SEC Form 4 · accession 0001615774-18-004023
ANAVEX LIFE SCIENCES CORP. · AVXL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sandra Boenisch
Officer — PFO & Treasurer
Period of report
May 15, 2018
Accepted (ET)
May 17, 2018 · 5:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001314052
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.30 | May 15, 2018 | A | 30,000 | A | — | May 15, 2028 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1The options shall vest upon the achievement of certain performance criteria in connection with clinical trial milestones.